Table 1 Correlation between ROD and the clinicopathological features of patients with metastatic renal cell carcinoma
Characteristics | Total | ROD < 1.34 (n = 83) | ROD ≥ 1.34 (n = 130) | p value |
|---|---|---|---|---|
Age at sunitinib (mean ± SD) | 53.3 ± 9.8 | 52.1 ± 10.7 | 54.1 ± 9.2 | 0.139 |
Gender, n (%) | 0.961 | |||
Man | 139 (65.3) | 54 (38.8) | 85 (61.2) | |
Woman | 74 (34.7) | 29 (39.2) | 45 (60.8) | |
KPS score < 80, n (%) | 15 (7.0) | 5 (33.3) | 10 (66.7) | 0.643 |
Presenting symptom, n (%) | 19 (8.9) | 7 (36.8) | 12 (63.2) | 0.842 |
Tumor size (mean ± SD) | 6.3 ± 2.2 | 6.7 ± 2.1 | 6.1 ± 2.2 | 0.089 |
Tumor location, n (%) | 0.182 | |||
Left | 102 (47.9) | 35 (34.3) | 67 (65.7) | |
Right | 111 (52.1) | 48 (43.2) | 63 (56.8) | |
Type of metastasis | 0.908 | |||
Synchronous | 96 (45.1) | 37 (24.0) | 59 (76.0) | |
Metachronous | 117 (54.9) | 46 (51.3) | 71 (48.7) | |
cT stage, n (%) | 0.012 | |||
cT1/2 | 199 (93.4) | 82 (41.2) | 117 (58.8) | |
cT3/4 | 14 (6.6) | 1 (7.1) | 13 (92.9) | |
pT stage, n (%) | 0.021 | |||
pT1/2 | 188 (88.3) | 82 (38.5) | 106 (49.8) | |
pT3/4 | 25 (11.7) | 1 (0.5) | 24 (11.2) | |
WHO/ISUP grade, n (%) | 0.010 | |||
I/II | 131 (61.5) | 60 (45.8) | 71 (54.2) | |
III/IV | 82 (38.5) | 23 (28.0) | 59 (72.0) | |
Tumor necrosis, n (%) | 69 (32.4) | 20 (29.0) | 49 (71.0) | 0.039 |
Sarcomatoid differentiation, n (%) | 43 (20.2) | 9 (20.9) | 34 (79.1) | 0.007 |
MSKCC risk classification | < 0.001 | |||
Good | 102 (47.9) | 59 (57.8) | 43 (42.2) | |
Intermediate and poor | 111 (52.1) | 24 (21.6) | 87 (78.4) | |
IMDC risk classification | < 0.001 | |||
Good | 92 (43.2) | 52 (56.5) | 40 (43.5) | |
Intermediate and poor | 121 (56.8) | 31 (25.6) | 90 (74.4) | |
Number of metastatic organs | 0.943 | |||
< 2 | 61 (28.6) | 24 (39.3) | 37 (60.7) | |
≥ 2 | 152 (71.4) | 59 (38.8) | 93 (61.2) | |
Response to sunitinib, n (%) | 0.844 | |||
Responder | 22 (10.3) | 9 (40.9) | 13 (59.1) | |
Non-responder | 191 (89.7) | 74 (38.7) | 117 (61.3) |